Interferon-beta treatment in multiple sclerosis patients decreases the number of monocytes in peripheral blood

Anlar O., Tombul T., Ozbek H., Dilek L.

NEUROSCIENCE RESEARCH COMMUNICATIONS, vol.32, no.2, pp.77-81, 2003 (Peer-Reviewed Journal) identifier identifier

  • Publication Type: Article / Article
  • Volume: 32 Issue: 2
  • Publication Date: 2003
  • Doi Number: 10.1002/nrc.10061
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.77-81
  • Keywords: multiple sclerosis, interferon therapy, monocytes, peripheral blood, EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS, MS PATIENTS, LEWIS RATS, IFN-BETA, T-CELLS, MACROPHAGES, ACTIVATION, DEATH


Multiple sclerosis (MS) is a demyelinating disease of the central nervous system, characterized by the presence of sclerotic lesions throughout the brain. During clinical activity, monocytes activation markers such as Interleukin 1 and tumor necrosis factor-alpha (TNF-alpha) increase. The effect of interferon beta (IFN-beta) in reducing exacerbation rate and in slowing sustained worsening of disability has been shown in MS. The aim of this study was to determine levels of monocytes percentage in peripheral blood of MS patients receiving IFN-beta.